<DOC>
	<DOCNO>NCT02772562</DOCNO>
	<brief_summary>The purpose study see well PROSTVAC -V/F work stop prostate cancer come back relapse . This study also look safety PROSTVAC-V/F .</brief_summary>
	<brief_title>Adjuvant PROSTVAC-V/F Subjects High Risk Relapse After Radical Prostatectomy</brief_title>
	<detailed_description>This study adult male patient recently undergone radical prostatectomy high risk relapse . The purpose study look effect PROSTVAC-V/F preventing prolong relapse surgery . PROSTVAC-V/F investigational drug .</detailed_description>
	<mesh_term>Prostatic Neoplasms</mesh_term>
	<criteria>Age &gt; /= 21 willing give consent Completed radical prostatectomy pathologicallyverified adenocarcinoma prostate 120 day prior enrollment . Postoperative PSA &lt; 0.2ng/mL 120 day prostatectomy Must one following : pT3b pT4 primary tumor ; Gleason score 810 ; pN1 lymph node disease ; positive surgical margin ; preoperative PSA &gt; 10ng/mL Patients pT3a disease lack one criterion , refuse adjuvant radiation , may also enrol . ECOG performance status 01 Adequate hematologic , renal , liver function outline protocol . Subject father potential must use adequate method contraception avoid conception throughout study least 4 week last dose study drug minimize risk pregnancy . Subjects must able start study drug within 90 day surgery . Subjects must negative bone scan , CT abdomen pelvis within 16 week prior enrollment . Pure small cell carcinoma prostate Radiographicallydemonstrable metastasis time prior time enrollment Diagnosis cancer require systemic therapy past 5 year Presence major medical condition , opinion investigator , preclude participation study Neoadjuvant adjuvant therapy kind Chronic administration ( defined daily every day continue use &gt; 14 day ) systemic glucocorticoid within 28 day first plan dose PROSTVACV/F . Use inhaled steroid , nasal spray , topical preparation small body area allow . Use systemic immunosuppressant agent include antimetabolite , glucocorticoid , TNF antagonists , antibody IL6 IL6R , calcineurin inhibitor , mTOR antagonist Prior history serious toxicity systemic reaction vaccinia immunization myopericarditis progressive vaccinia infection , eczema vaccinatum . Inflammatory exfoliative skin disease eczema , psoriasis disrupt epidermis Active infection require systemic therapy History serologic evidence chronic viral infection ( hepatitis B C ) , HIV/AIDS History allergy egg , egg product , aminoglycoside antibiotic History myocardial disease , myocarditis , cardiomyopathy , congestive heart failure , ischemic cardiomyopathy Prior solid organ stem cell transplant History active autoimmune disease ( e.g. , autoimmune neutropenia , thrombocytopenia , hemolytic anemia , systemic lupus , localize lupus , Sjogren 's syndrome , scleroderma , myasthenia gravis , Goodpasture 's syndrome , Addison 's disease , Hashimoto 's thyroiditis , Graves disease ) . Persons vitiligo exclude . Uncontrolled diabetes . Subjects diabetes excluded condition wellcontrolled ( A1C &lt; 7.5 ) Vaccination live attenuate vaccine within 28 day prior day 1 PROSTVACV/F administration vaccination kill vaccine within 14 day prior day 1 PROSTVACV/F . Inability avoid close contact household contact follow highrisk individual three week Day 1 vaccination vaccination site heals completely : ( ) child â‰¤ 3 year age , ( b ) pregnant nursing woman , ( c ) individual prior concurrent extensive eczema eczemoid skin disorder , ( ) immunocompromised individual , HIV . Any condition , opinion investigator , would prevent full participation trial ( include FollowUp ) , would interfere evaluation trial endpoint .</criteria>
	<gender>Male</gender>
	<minimum_age>21 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2016</verification_date>
	<keyword>prostate cancer</keyword>
</DOC>